CpG motifs are efficient adjuvants for DNA cancer vaccines

Journal of Investigative Dermatology

Volumn 123, Issue 2, 2004, Pages 371-379

  Schneeberger, Achim ^a   Wagner, Christine ^a,b   Zemann, Anja ^c   Lührs, Petra ^a   Kutil, Raphaela ^a   Goos, Manfred ^c   Stingl, Georg ^a,b   Wagner, Stephan N ^a,b  

^a Universitatsklinik fur Dermatologie   (Austria)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

CpG motifs; CTL; Melanoma; pDNA; Tumor immunity

Indexed keywords

ADJUVANT; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; MELANOMA ANTIGEN; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CELL ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; CPG ISLAND; DNA STRUCTURE; FEMALE; IMMUNE RESPONSE; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; MODEL; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTECTION; PROVOCATION TEST; T LYMPHOCYTE; TUMOR CELL;

EID: 3242656979     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2004.23208.x     Document Type: Article

References (55)

1. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H: Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 32:1958-1968, 2002
2. Arpinati M, Chirumbolo G, Urbini B, Perrone G, Rondelli D, Anasetti C: Role of plasmacytoid dendritic cells in immunily and tolerance after allogeneic hematopoietic stem cell transplantation. Transpl Immunol 11:345-356, 2003
3. Baines J, Celis E: Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res 9:2693-2700, 2003
4. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ: Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 167:4878-4886, 2001
5. Baral RN, Saha A, Chatterjee SK, Foon KA, Krieg AM, Weiner GJ, Bhattacharya-Chatterjee M: Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen. Cancer Immunol Immunother 52:317-327, 2003
6. Bauer S, Kirschning CJ, Hacker H, et al: Humar TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 98:9237-9242, 2001a
7. Bauer M, Redecke V, Ellwart JW, Scherer B, Kremer JP, Wagner H, Lipford GB: Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J Immunol 166:5000-5007, 2001b
8. Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, Sandstrom E, Wahren B: Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351:1320-1325, 1998
9. Carpentier AF, Xie J, Mokhtari K, Delattre JY: Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 6:2469-2473, 2000
10. Cohen AD, Boyer JD, Weiner DB: Modulating the immune response to genetic immunization. FASEB J 12:1611-1626, 1998
11. Cox AL, Skipper J, Chen Y, et al: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-719, 1994
12. Davila E, Kennedy R, Celis E: Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 63:3281-3288, 2003
13. Donnelly J, Berry K, Ulmer JB: Technical and regulatory hurdles for DNA vaccines. Int J Parasitol 33:457-467, 2003
14. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA: DNA vaccines. Annu Rev Immunol 15:617-648, 1997
15. Finn OJ: Cancer vaccines: Between the idea and the reality. Nat Rev Immunol 3:630-641, 2003
16. Herweijer H, Wolff JA: Progress and prospects: Naked DNA gene transfer and therapy. Gene Ther 10:453-458, 2003
17. Hornung V, Rothenfusser S, Britsch S, et al: Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivi y to CpG oligodeoxynucleotides. J Immunol 168:4531-4537, 2002
18. Kadowaki N, Antonenko S, Liu YJ: Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c-type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J Immunol 166:2291-2295, 2001
19. Kawakami Y, Eliyahu S, Jennings C, et al: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968, 1995
20. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hammerling GJ: NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 167:5247-5253, 2001
21. Krieg AM: CpG motifs in bacterial DNA anc their immune effects. Annu Rev Immunol 20:709-760, 2002
22. Krieg AM: CpG motif: The active ingredient in bacterial extracts? Nat Med 9:831-835, 2003
23. Krieg AM, Wu T, Weeratna R, et al: Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA 95:12631-12636, 1998
24. Krieg AM, Yi AK, Matson S, et al: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549, 1995
25. Krug A, Towarowski A, Britsch S, et al: Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 31:3026-3037, 2001
26. Lanuti M, Rudginsky S, Force SD, et al: Cationic lipid: Bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res 60:2955-2963, 2000
27. Luhrs P, Schmidt W, Kutil R, Buschle M, Wagner SN, Stingl G, Schneeberger A: Induction of specific immune responses by polycation-based vaccines. J Immunol 169:5217-5226, 2002
28. MacGregor GR, Caskey CT: Construction of plasmids that express E. coli beta-galactosidase in mammalian cells. Nucleic Acids Res 17:2365, 1989
29. McConkey SJ, Reece WH, Moorthy VS, et al: Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9:729-735, 2003
30. Miconnet I, Koenig S, Speiser D, Krieg A, Guillaume P, Cerottini JC, Romero P: CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 168:1212-1218, 2002
31. Mor G, Klinman DM, Shapiro S, et al: Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA. J Immunol 155:2039-2046, 1995
32. Prosch S, Stein J, Staak K, Liebenthal C, Volk HD, Kruger DH: Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Biol Chem Hoppe Seyler 377:195-201, 1996
33. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature 411:380-384, 2001
34. Roy MJ, Wu MS, Barr LJ, et al: Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19:764-778, 2000
35. Sandler AD, Chihara H, Kobayashi G, Zhu X, Miller MA, Scott DL, Krieg AM: CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res 63:394-399, 2003
36. Sato Y, Roman M, Tighe H, et al: Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273:352-354, 1996
37. Schmitt E, Hoehn P, Germann T, Rude E: Differential effects of interleukin-12 on the development of naive mouse CD4+ T cells. Eur J Immunol 24:343-347, 1994
38. Schneeberger A, Koszik F, Schmidt W, Kutil R, Stingl G: The tumorigenicity of IL-2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defense reaction: NK cells play a major role. J Immunol 162:6650-6657, 1999
39. Schreurs MW, de Boer AJ, Schmidt A, Figdor CG, Adema GJ: Cloning, expression and tissue distribution of the murine homologue of the melanocyte lineage-specific antigen gp100. Melanoma Res 7:463-470, 1997
40. Spack EG, Sorgi FL: Developing non-viral DNA delivery systems for cancer and infectious disease. Drug Discov Today 6:186-197, 2001
41. Sparwasser T, Vabulas RM, Villmow B, Lipford GB, Wagner H: Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol 30:3591-3597, 2000
42. St George JA: Gene therapy progress and prospects: Adenoviral vectors. Gene Ther 10:1135-1141, 2003
43. Stopeck AT, Hersh EM, Akporiaye ET, et al: Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 15:341-349, 1997
44. Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, Edelman R: Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17:2826-2829, 1999
45. Tagawa ST, Lee P, Snively J, et al: Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 98:144-154, 2003
46. Tighe H, Corr M, Roman M, Raz E: Gene vaccination: Plasmid DNA is more than just a blueprint. Immunol Today 19:89-97, 1998
47. Wagner SN, Wagner C, Höfler H, Atkinson MJ, Goos M: Expression cloning of the cDNA encoding a melanoma-associated antigen recognized by monoclonal antibody HMB-45: Identification as melanocyte-specific Pmel 17 cDNA. Lab Invest 73:229-235, 1995
48. Wagner SN, Wagner C, Luhrs P, et al: Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo. J Invest Dermatol 115:1082-1087, 2000
49. Wang R, Doolan DL, Le TP, et al: Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282:476-480, 1998
50. Wang R, Epstein J, Baraceros FM, et al: Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA 98:10817-10822, 2001
51. Wild J, Grusby MJ, Schirmbeck R, Reimann J: Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4 + T cell dependent. J Immunol 163:1880-1887, 1999
52. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ: Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89:2994-2998, 1997
53. Yasumura Y, Buonassisi V, Sato G: Clonal analysis of differentiated function in animal cell cultures. I. Possible correlated maintenance of differentiated function and the diploid karyotype. Cancer Res 26:529-535, 1966
54. Zhai Y, Yang JC, Spiess P, et al: Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother 20:15-25, 1997
55. Zwaveling S, Ferreira Mota SC, Nouta J, et al: Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169:350-358, 2002